Ken Horne, ANV managing partner
July 1, 2025 04:00 PM EDTUpdated 05:04 PM
Financing
Startups

Ex­clu­sive: VC firm lines up $200M fund to cham­pi­on Japan­ese in­no­va­tion

Kyle LaHucik

Biotech Correspondent

At a time when few biotech ven­ture cap­i­tal firms are com­ing out of the gates, a Japan-fo­cused in­vestor is do­ing so and has closed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill

Broad In­sti­tute con­ducts lay­offs as it preps for cuts in fed­er­al fund­ing; Dyne’s fi­nanc­ing

Kevin Tang's Con­cen­tra snags an­oth­er buy­out, this time for IGM Bio­sciences

Pfiz­er ends Phase 1b/2 tri­al for fi­nal Tril­li­um CD47 drug

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

A service from the Financial Times